ClinicalTrials.gg
RecruitingNCT05754593FEMINISEPUpdated Oct 27, 2026

Study of Ovarian Reserve Concerning Patients With Multiple Sclerosis (MS), Compared to a Control Group

An interventional study of Anti-Mullerian hormone (AMH) level and Antral follicle count (AFC) in Multiple Sclerosis, sponsored by University Hospital, Bordeaux. Recruiting at 1 site in France. Open to female participants aged 25 Years to 35 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by University Hospital, Bordeaux · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 11 months later.
Updated Oct 27, 2026Primary completion movedStudy completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
160
Allocation
Non-randomized
Ages
25 Years to 35 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Multiple Sclerosis by University Hospital, Bordeaux — 3 open to participants now, 3 under way, none of them phase 3. Multiple Sclerosis · University Hospital, Bordeaux.

Planned enrollment
2nd of 13
160 · median 65
Started
2023
with 2 others
No phase
11 of 17
3 open now
Registered
17th of 17
by date

Among the 17 studies in Multiple Sclerosis by University Hospital, Bordeaux, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 3 that started in 2023, is one of 11 with no phase, and was the 17th registered.

Multiple Sclerosis

3,273 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.

Browse Multiple Sclerosis studies →

Open to participants now

3 of the 17 studies in Multiple Sclerosis by University Hospital, Bordeaux are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 434 Multiple Sclerosis studies recruiting now, 164 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 95 take healthy volunteers.

This study: 25 Years to 35 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Multiple Sclerosis by University Hospital, Bordeaux, or all of them as a file.
02

Study summary

The investigators want to evaluate ovarian reserve concerning patients with multiple sclerosis, compared to a control group of healthy women. This study will include women from 25 to 35 years old.

Read the detailed description

Multiple sclerosis is an inflammatory disease of central nervous system, with a prevalence rate in France of 1 case/1000 subjects. The average age at diagnosis is 30 years old and it affects especially women, with a sex ratio of 3 women for 1 men. Multiples sclerosis concerns women at a moment when fertility is a main issue.

Few studies suggest that there is an negative impact of multiple sclerosis on ovarian reserve, with a combined mechanism ( inflammatory and autoimmune mechanism). The investigators can hypothesize that patients with multiple sclerosis are more predisposed to have primary ovarian insufficiency.

Ovarian reserve is evaluated by Anti-Mullerian Hormone (AMH) dosage and antral follicle count (AFC) by ultrasound imaging.AMH levels can be measured at every moment of the menstrual cycle whereas AFC is preferentially performed between the second and the eighth day of the menstrual cycle. The combined use of this two markers is well known to be correlated with ovarian reserve. Only a few studies have evaluated ovarian reserve in patients with multiple sclerosis. Besides, there is only a few number of participants and results are contradictory. A decrease of ovarian reserve identified among patients with multiple sclerosis could lead to an orientation in a fertility preservation center.

This project is a monocentric study realized at Pellegrin Hospital - Bordeaux. Patients with multiple sclerosis belong to a cohort of the neurology center. Healthy women come from a volunteer base contacted by email.The two groups are matched thanks to answers of a short questionnaire.Measure of AMH level is performed at pellegrin Hospital at the medical laboratory. Ultrasound imaging is performed by the center of women imagery at Pellegrin Hospital. Results are communicated by teleconsultation two months later. If there is an anormal result, a specific appointment will be organized with a gynecologist.

03

Conditions studied

  • Multiple Sclerosis

Browse trials for

Keywords

  • multiple sclerosis
  • ovarian reserve
  • fertility
  • auto-immunity
04

Who can participate

Ages eligible
25 Years to 35 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Reproductive women between 25 and 35 years old ;
  • MS Patient : Diagnosis of multiple sclerosis based on McDonald Criteria 2017;
  • French-speaking, without comprehension disorders ;
  • being affiliated to health insurance ;
  • Willing to participate and to sign .

Exclusion criteria

Exclusion Criteria:

  • History of ovarian surgery (cystectomy, annexectomy) ;
  • Turner Syndrome ;
  • fragile X messenger ribonucleoprotein 1 (FMR1) premutation ;
  • Endometriosis with a risk of ovarian reserve alteration ;
  • History of chemotherapy or pelvic radiotherapy ;
  • Pregnant or breastfeeding women ;
  • patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    MS patients

    Diagnosis of multiple sclerosis based on McDonald Criteria 2017

    Biological: Anti-Mullerian hormone (AMH) level · Other: Antral follicle count (AFC) · Other: Clinical assessment

  • Active comparator
    Controls

    Healthy controls

    Biological: Anti-Mullerian hormone (AMH) level · Other: Antral follicle count (AFC)

Interventions

  • BiologicalAnti-Mullerian hormone (AMH) level

    Measure of Anti-Mullerian hormone (AMH) level by blood sample

  • OtherAntral follicle count (AFC)

    Measure of Antral follicle count (AFC) by ultrasound imaging

  • OtherClinical assessment

    MS history and MS treatments and Expanded Disability Status Scale (EDSS) score will be recorded

06

What researchers measure

Primary outcomes

  1. Measure of Anti-Mullerian hormone (AMH) level by blood sample to compare ovarian reserve between patients with multiple sclerosis versus healthy controls from 25 to 35 years old.

    Time frame: At baseline (day 0)

Secondary outcomes

  1. Measure of Antral follicle count (AFC) by ultrasound imaging to compare ovarian reserve between patients with multiple sclerosis versus healthy controls from 25 to 35 years old.

    Time frame: At baseline (day 0)

07

Study locations

1 of 1 sites recruiting
  • CHU de Bordeaux - service de neurologie
    Bordeaux, France
    Recruiting
    • Valérie BERNARD, MD · Contactvalerie.bernard@chu-bordeaux.fr · (0)5 56 79 56 79
    • Katy-Kim LATASTE, PhD · Contactkaty-kim.lataste@chu-bordeaux.fr · (0)5.57.82.25.10
    • Valérie BERNARD, MD · Principal investigator
    • Jean-Christophe OUALLET, MD · Sub investigator
    • Pauline BOISSONNIERE, MD · Sub investigator
    • Pauline BOUCHARD, MD · Sub investigator
    • Arnaud GAGNOL, MD · Sub investigator
    • Aurélie RUET, Prof · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2027, 48 months after the start.

Of 852 non-industry interventional studies with no phase under Multiple Sclerosis, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 43. This study's planned 48 months is above that.

Counting every sponsor, half of 874 studies reached it within 21 months; a quarter within 9 and three quarters within 43.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Dec 2026 → Dec 2027 and completion Dec 2026 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 21, 2023
First posted
Mar 6, 2023
StartActual
Dec 4, 2023
Primary completionEst.
Dec 2027was Dec 2026
CompletionEst.
Dec 2027was Dec 2026
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 2026→Dec 2027
Oct 27, 2026
Study completion
Dec 2026→Dec 2027
Oct 27, 2026
Contact
Study contact changed: m•••@chu-bordeaux.fr · •••1275→k•••@chu-bordeaux.fr · •••2510. See the current contact
Oct 27, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • CHU de Bordeaux - service de neurologie · Bordeaux, FranceContact m•••@chu-bordeaux.fr · •••1275→k•••@chu-bordeaux.fr · •••2510Contact removed (no phone or email listed)
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    Primary completion Dec 2026→Dec 2027
    Study completion Dec 2026→Dec 2027
    Contact Study contact changed: m•••@chu-bordeaux.fr · •••1275→k•••@chu-bordeaux.fr · •••2510. See the current contact
    Site contacts Changed at 1 site. See the sites
    Show the site
    • CHU de Bordeaux - service de neurologie · Bordeaux, FranceContact m•••@chu-bordeaux.fr · •••1275→k•••@chu-bordeaux.fr · •••2510Contact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05754593
Responsible party
Sponsor
First posted
Mar 6, 2023
Start date
Dec 4, 2023
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Oct 27, 2026

Study contacts

Valérie BERNARD, MD
Contact
valerie.bernard@chu-bordeaux.fr
(0)5 56 79 56 79 ext. +33
Katy-Kim LATASTE, PhD
Contact
katy-kim.lataste@chu-bordeaux.fr
(0)5.57.82.25.10 ext. +33
Valérie BERNARD, MD
principal investigator · University Hospital, Bordeaux
Antoine BERNARD, MD
study chair · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion